Eterna Therapeutics (ERNA) News Today $0.25 +0.00 (+1.05%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Eterna Therapeutics Inc Ordinary SharesDecember 5, 2024 | morningstar.comEterna launches research to evaluate ERNA-101December 3, 2024 | markets.businessinsider.comEterna Therapeutics Authorized $1 Mln Share Buyback; Stock Up In Pre-marketNovember 25, 2024 | markets.businessinsider.comEterna Therapeutics Announces Up to $1 Million Stock Repurchase ProgramNovember 25, 2024 | markets.businessinsider.comEterna regains compliance with NasdaqNovember 14, 2024 | markets.businessinsider.comEterna Therapeutics Regains Compliance with NASDAQ for Continued ListingNovember 14, 2024 | globenewswire.comEterna files to sell 49.87M shares of common stock for holdersNovember 7, 2024 | markets.businessinsider.comEterna completes strategic financial restructuringOctober 31, 2024 | markets.businessinsider.comEterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term SuccessOctober 30, 2024 | globenewswire.comEterna, Factor announce license, collaboration agreementOctober 19, 2024 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare DiseasesOctober 17, 2024 | globenewswire.comCoeptis Therapeutics (NASDAQ:COEP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEterna Therapeutics Inc. (ERNA)September 19, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 10, 2024 | globenewswire.comEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardMay 8, 2024 | globenewswire.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusMay 7, 2024 | finance.yahoo.comQ4 2023 Cognition Therapeutics Inc Earnings CallMarch 27, 2024 | finance.yahoo.comViking Therapeutics' experimental tablet helps reduce weight in small studyMarch 26, 2024 | msn.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023March 15, 2024 | investorplace.comEterna Therapeutics Stock (NASDAQ:ERNA) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | finance.yahoo.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | globenewswire.comEterna Therapeutics files to sell 18.2M shares for holdersJanuary 12, 2024 | msn.comEterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)January 3, 2024 | finance.yahoo.comEterna Therapeutics Appoints Sanjeev Luther as President and CEODecember 21, 2023 | finance.yahoo.comEterna Therapeutics names Sanjeev Luther as CEODecember 20, 2023 | msn.comEterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerDecember 20, 2023 | finance.yahoo.comEterna Therapeutics launches convertible debt and warrant financing of up to $9.2MDecember 15, 2023 | msn.comEterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingDecember 14, 2023 | finance.yahoo.comTreadwell Announces Strategic Pipeline Prioritization and Leadership TransitionsDecember 6, 2023 | markets.businessinsider.comTrading was temporarily halted for "ERNA" at 02:12 PM with a stated reason of "LULD pause."December 6, 2023 | marketbeat.comEterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of DirectorsNovember 1, 2023 | finance.yahoo.comCalidi Biotherapeutics Names Andrew Jackson CFOOctober 30, 2023 | markets.businessinsider.comCalidi Biotherapeutics Names Andrew Jackson Chief Financial OfficerOctober 30, 2023 | marketwatch.comPositive Clinical Outcomes and Continued Genentech Support Bolster Buy Rating for Lineage Cell Therapeutics: An Analysis of OpRegen’s PotentialOctober 5, 2023 | markets.businessinsider.comStem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: VisiongainSeptember 13, 2023 | uk.finance.yahoo.comInsider Stock Buying Reaches US$2.7m On Eterna TherapeuticsSeptember 8, 2023 | finance.yahoo.comEterna Therapeutics Teams with Lineage Cell on Transplant TherapiesSeptember 6, 2023 | finance.yahoo.comEterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell TherapeuticsSeptember 6, 2023 | finance.yahoo.comEterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of DirectorsSeptember 5, 2023 | finance.yahoo.comEterna Therapeutics Appoints Dorothy Clarke to Board of DirectorsSeptember 5, 2023 | finance.yahoo.comEterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt FinancingJuly 18, 2023 | finance.yahoo.comEterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of DirectorsJuly 11, 2023 | finance.yahoo.comEterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General CounselMay 24, 2023 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 17, 2023 | finance.yahoo.comEterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 4, 2023 | finance.yahoo.comEterna Therapeutics Shares Rise 11% After Offer for Exacis Biotherapeutics AssetsMay 2, 2023 | marketwatch.comEterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis BiotherapeuticsMay 2, 2023 | finance.yahoo.comEterna Therapeutics Agrees to $10M Stock Purchase with Lincoln Park CapitalApril 11, 2023 | marketwatch.com Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> ERNA Media Mentions By Week ERNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERNA News Sentiment▼0.000.60▲Average Medical News Sentiment ERNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERNA Articles This Week▼00▲ERNA Articles Average Week Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GTBP News HOTH News CANF News ELAB News IMCC News BMRA News AEZS News PPBT News BNOX News UPXI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERNA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
